Has Michael Digiovanna, MD received payments from drug or device companies?

Yes. Drug and device makers reported $5,342 in general payments to Michael Digiovanna, MD across 22 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Michael Digiovanna, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Michael Digiovanna, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Michael Digiovanna, MD

Medical Oncology · New Haven, CTNPI 1023006947

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $3,600 of the $5,342 with a category attached, or 67.4%. Bayer accounts for 67.4% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2021 at $3,661 and has fallen 96.2% since, to $140 in 2025.

$5,342in general payments, 2019–2025

Across 22 payments — averaging $242.83 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Bayer$4K
F. Hoffmann-la Roche AG$1K
Sumitomo Pharma America, Inc.$246
Xeris Pharmaceuticals, Inc.$140
GSK$111
AbbVie$37
plus $40 from 2 others

$2,467,570in research payments, 2019–2025

Across 92 payments — averaging $26,821 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Boehringer Ingelheim$2.2M
Seagen Inc.$235K
F. Hoffmann-la Roche AG$4K
Boehringer Ingelheim International GmbH$4K
GSK$1K
Merck$902

What the payments were for

Consulting fees$3,60067%
Speaking & faculty fees$1,16722%
Food & beverage$56311%
Education$120%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Bayer	1	$3,600
F. Hoffmann-la Roche AG	4	$1,167
Sumitomo Pharma America, Inc.	3	$246
Xeris Pharmaceuticals, Inc.	2	$140
GSK	7	$111
AbbVie(2 entities)	2	$37
Gilead	2	$28
Lilly USA, LLC	1	$12

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,342 in reported general payments places this provider in the 55th percentile of 79 medical oncology providers in Connecticut.

See all medical oncology providers in Connecticut →

Medicare billing

Part B allowed, 2024

$19,166

Medicare patients

Services billed

173

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Letrozole	54	$977
Tamoxifen Citrate	22	$744

Paid to pharmacies, not to this prescriber.

Other medical oncology in New Haven

Peter MarksNew Haven$578K
Daniel PetrylakNew Haven$446K
Mandar MuzumdarNew Haven$371K
Barbara BurtnessNew Haven$297K
Ian KropNew Haven$219K
Francine FossNew Haven$193K
Anne ChiangNew Haven$158K
Mario SznolNew Haven$157K
Lajos PusztaiNew Haven$152K
Howard HochsterNew Haven$133K

See the full list for Connecticut →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →